What this deck covers
This deck focuses on Antimicrobial And Opioid Stewardship, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Antimicrobial And Opioid Stewardship in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
What is the preferred targeted therapy for MSSA bacteremia: vancomycin or a beta-lactam?
Tap card or press Space to flip
A beta-lactam (nafcillin/oxacillin or cefazolin). Beta-lactams provide superior efficacy against MSSA compared to alternatives like vancomycin.
How well did you know it?
Card 1 / 23
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Antimicrobial And Opioid Stewardship, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: A beta-lactam (nafcillin/oxacillin or cefazolin). Beta-lactams provide superior efficacy against MSSA compared to alternatives like vancomycin.
Answer: Standardized opioid dose expressed as mg morphine per day. MME standardizes comparison of opioid potencies to assess daily exposure and risk.
Answer: Optimize outcomes while minimizing resistance, toxicity, and cost. Antimicrobial stewardship balances effective treatment with reducing risks to improve patient care and public health.
Answer: De-escalate or discontinue antibiotics if no bacterial source. Negative cultures and improvement suggest non-bacterial etiology, warranting stewardship-driven de-escalation.
Answer: Opioids with benzodiazepines. Concurrent use heightens respiratory depression risk, a critical concern in opioid stewardship.
Answer: Avoid or discontinue antibiotics. Antibiotics are ineffective against viruses and contribute to resistance and adverse effects when misused.
Answer: Reassess indication, drug, dose, duration at 48–72 hours. Antibiotic time-out ensures ongoing appropriateness of therapy by systematic review after initial empiric treatment.
Answer: Vancomycin. Vancomycin effectively covers MRSA, unlike beta-lactams such as cefazolin which lack activity against it.
Answer: Nonopioids and nonpharmacologic therapies. Guidelines prioritize safer alternatives to mitigate long-term opioid risks in chronic pain management.
Answer: Co-prescribe naloxone for patients at increased risk. Naloxone provides a reversal agent for potential opioid overdose in high-risk scenarios.
Answer: Do not treat; asymptomatic bacteriuria. Absence of symptoms indicates colonization, not infection, avoiding unnecessary antibiotics per guidelines.
Answer: Narrow or stop therapy based on cultures and clinical response. De-escalation refines antibiotic therapy to the most appropriate regimen once diagnostic information is available.
Answer: Prospective audit and feedback. Prospective audit and feedback allows post-initiation review to optimize ongoing antibiotic therapy.
Answer: IV-to-PO conversion. IV-to-PO conversion reduces hospital stay, costs, and complications while maintaining efficacy in suitable patients.
Answer: Optimize pain control while minimizing misuse, overdose, and harm. Opioid stewardship focuses on effective pain management while addressing risks associated with opioid use.
Answer: Enables targeted therapy and de-escalation. Cultures identify specific pathogens, allowing for precise antibiotic selection and reduced broad-spectrum use.
Answer: Do not treat (exceptions: pregnancy, urologic procedures). Treating asymptomatic bacteriuria promotes resistance and adverse effects without clinical benefit in most cases.
Answer: Increases adverse effects and C. difficile risk without benefit. Unnecessary anaerobic coverage exposes patients to avoidable risks without improving outcomes.
Answer: Pregnancy. Asymptomatic bacteriuria in pregnancy risks pyelonephritis and adverse fetal outcomes, necessitating treatment.
Answer: At least 60 mg oral morphine equivalents daily for 7 days. This threshold indicates physiological adaptation, guiding dosing adjustments in opioid management.
Answer: Avoid combination; reduce/stop one agent and consider naloxone. Combination increases sedation and respiratory risks, especially with OSA, requiring intervention to mitigate harm.
Answer: Start low and titrate based on response and adverse effects. Low starting doses minimize risks like respiratory depression in patients without opioid tolerance.
Answer: Preauthorization. Preauthorization restricts broad-spectrum antibiotics to justified cases, promoting judicious use from the outset.